Skip to content

Author

T. Prohaska

We have 4 of 39 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Long-term efficacy and safety of olezarsen in patients with severe hypertriglyceridemia

Olezarsen, an antisense oligonucleotide that targets the mRNA for apolipoprotein C-III, reduced triglycerides (TGs) in patients with severe hypertriglyceridemia (sHTG, TG >500 mg/dL) by 50-72% at 6 months in two double-blinded placebo-controlled randomized clinical trials (RCTs, CORE-TIMI 72a, CORE2-TIMI 72b)....

R. Giugliano, N. Marston, B. Bergmark et al. · 0 citations
Open access Oct 2026

ION775, a long-acting siRNA targeting APOC3: single-dose, 12-month results in participants with moderate hypertriglyceridemia

Single subcutaneous doses of ION775 produced rapid, significant, dose-dependent, and durable reductions in apoC-III and TGs, with favorable effects on atherogenic lipoprotein measures and an acceptable safety profile through up to 12 months of follow-up.

S. Tsimikas, E. Morgan, J. Sharma et al. · 0 citations
Open access Aug 2026

Single-dose ION775, a GalNAc-conjugated siRNA targeting APOC3, lowers triglycerides for up to 12 months in moderate hypertriglyceridemia.

BACKGROUND Apolipoprotein C-III (apoC-III) regulates triglyceride-rich lipoprotein metabolism. ION775 is a GalNAc-conjugated small interfering RNA designed to silence APOC3 mRNA and enable infrequent dosing. OBJECTIVE To evaluate the safety, tolerability, and lipid effects of single-dose ION775 in adults with moderat...

S. Tsimikas, Erin S. Morgan, Jyoti Sharma et al. · 0 citations
Aug 2026

Efficacy and safety of olezarsen in patients with vs without baseline fibrate use.

Olezarsen reduced triglycerides across the hypertriglyceridemia spectrum, with greater effects in patients on background fibrates, particularly with diabetes, to support potential complementary mechanisms and further investigation of concomitant triglyceride-reducing therapy.

Annabel Z. Wang, V. Alexander, T. Prohaska et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.